These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 9403321)

  • 1. Insulin regulation of human ovarian androgens.
    Nestler JE
    Hum Reprod; 1997 Oct; 12 Suppl 1():53-62. PubMed ID: 9403321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity and the polycystic ovary syndrome.
    Gambineri A; Pelusi C; Vicennati V; Pagotto U; Pasquali R
    Int J Obes Relat Metab Disord; 2002 Jul; 26(7):883-96. PubMed ID: 12080440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
    Nestler JE
    Semin Reprod Endocrinol; 1997 May; 15(2):111-22. PubMed ID: 9165656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycystic ovary syndrome and anti-Müllerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins.
    Cassar S; Teede HJ; Moran LJ; Joham AE; Harrison CL; Strauss BJ; Stepto NK
    Clin Endocrinol (Oxf); 2014 Dec; 81(6):899-906. PubMed ID: 25040369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.
    Rosenfield RL; Ehrmann DA
    Endocr Rev; 2016 Oct; 37(5):467-520. PubMed ID: 27459230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-lowering medications in polycystic ovary syndrome.
    Taylor AE
    Obstet Gynecol Clin North Am; 2000 Sep; 27(3):583-95. PubMed ID: 10958005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of caloric intake timing on insulin resistance and hyperandrogenism in lean women with polycystic ovary syndrome.
    Jakubowicz D; Barnea M; Wainstein J; Froy O
    Clin Sci (Lond); 2013 Nov; 125(9):423-32. PubMed ID: 23688334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperandrogenism, insulin resistance and acanthosis nigricans. 10 years of progress.
    Barbieri RL
    J Reprod Med; 1994 May; 39(5):327-36. PubMed ID: 8064699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nutrient-Induced Inflammation in Polycystic Ovary Syndrome: Role in the Development of Metabolic Aberration and Ovarian Dysfunction.
    González F
    Semin Reprod Med; 2015 Jul; 33(4):276-86. PubMed ID: 26132932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Source and amount of carbohydrate in the diet and inflammation in women with polycystic ovary syndrome.
    Barrea L; Marzullo P; Muscogiuri G; Di Somma C; Scacchi M; Orio F; Aimaretti G; Colao A; Savastano S
    Nutr Res Rev; 2018 Dec; 31(2):291-301. PubMed ID: 30033891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Fetuin-A levels, insulin resistance and oxidative stress in women with polycystic ovary syndrome.
    Enli Y; Fenkci SM; Fenkci V; Oztekin O
    Gynecol Endocrinol; 2013 Dec; 29(12):1036-9. PubMed ID: 23961784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polycystic ovarian syndrome: signs and feedback effects of hyperandrogenism and insulin resistance.
    Hernández-Jiménez JL; Barrera D; Espinoza-Simón E; González J; Ortíz-Hernández R; Escobar L; Echeverría O; Torres-Ramírez N
    Gynecol Endocrinol; 2022 Jan; 38(1):2-9. PubMed ID: 34787028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
    Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome.
    Holte J
    Baillieres Clin Endocrinol Metab; 1996 Apr; 10(2):221-47. PubMed ID: 8773746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome.
    Chen MJ; Yang WS; Yang JH; Chen CL; Ho HN; Yang YS
    Hypertension; 2007 Jun; 49(6):1442-7. PubMed ID: 17389259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Puberty and polycystic ovarian syndrome: the insulin/insulin-like growth factor I hypothesis.
    Nobels F; Dewailly D
    Fertil Steril; 1992 Oct; 58(4):655-66. PubMed ID: 1426306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum HLA-G levels in women with polycystic ovary syndrome.
    Oztekin O; Fenkci SM; Fenkci V; Enli Y; Cabus U
    Gynecol Endocrinol; 2015 Mar; 31(3):243-6. PubMed ID: 25403326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperinsulinism and its interaction with hyperandrogenism in polycystic ovary syndrome.
    Sozen I; Arici A
    Obstet Gynecol Surv; 2000 May; 55(5):321-8. PubMed ID: 10804539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of hyperinsulinaemia in women.
    Conway GS; Jacobs HS
    Clin Endocrinol (Oxf); 1993 Dec; 39(6):623-32. PubMed ID: 8287579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinaemia or lean normoinsulinaemia.
    Ciotta L; De Leo V; Galvani F; La Marca A; Cianci A
    Hum Reprod; 1999 Dec; 14(12):2951-8. PubMed ID: 10601077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.